Described herein are methods, compositions, and kits for forming engineered in vitro biomimetic, three-dimensional, tubular organoid structures by directed differentiation of human pluripotent stem cells within tubular channels formed in a hydrogel.

Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.

A method of forming a gel particle slurry includes providing a first solution that includes a cross-linkable hydrogel polymer macromer and an optional first crosslinker in a first depot and optionally a second solution in a second depot that is separated from the first depot by a mixing unit that includes a mixing element; and reversibly transferring the first solution and the optional second solution through the mixing unit between the first depot and the second depot such that the first solution and the optional second solution are mixed and agitated to form the gel particle slurry.

Methods fabricate an endothelialized myocardium usable for screening of a drug. A microfibrous hydrogel scaffold is manufactured with additive manufacturing that concurrently bioprints endothelial cells directly within the microfibrous hydrogel scaffold. A bioink is bioprinted into an arrangement of one or more microfibers. The bioink includes at least one crosslinking component and suspended endothelial cells. The crosslinking component or components are crosslinked to yield the microfibrous hydrogel scaffold having the endothelial cells embedded directly within. The microfibrous hydrogel scaffold is seeded with cardiomyocytes to yield the endothelialized myocardium with a controlled anisotropy. The endothelialized myocardium can be incubated until the endothelialized myocardium matures into spontaneously beating myocardial tissue having contractions aligned with the controlled anisotropy. The beating myocardial tissue can be used to screen a drug when the beating myocardial tissue is embedded within a microfluidic perfusion bioreactor.

The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

The disclosure provides 3D bioprinted test beds and methods of making the 3D bioprinted teste beds, methods of using the 3D bioprinted test beds for testing and/or comparatively testing two or more test compounds on cell growth and/or behavior, as well as biocompatible methacrylated hyaluronic acid-based bioinks for printing the 3D test beds and/or other articles. The 3D test beds and bioinks include a hydrogel material/precursor and can include extracellular matrix components.

The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

Provided are fast relaxing hydrogels that are useful for regulating cell behavior and enhancing tissue regeneration, e.g., bone regeneration.

A method or apparatus for creating a three-dimensional tissue construct of a desired shape for repair or replacement of a portion of an organism. The method may comprise injecting at least one biomaterial in a three-dimensional pattern into a first material such that the at least one biomaterial is held in the desired shape of the tissue construct by the first material. The apparatus may comprise an injector configured to inject at least one biomaterial in a three-dimensional pattern into a first material such that the at least one biomaterial is held in the desired shape of the tissue construct by the first material. The first material may comprise a yield stress material, which may be a material exhibiting Herschel-Bulkley behavior. The tissue construct may have a smallest feature size of ten micrometers or less.

Described herein is a method of generating in-vitro differentiated airway basal cells and compositions thereof. Also described herein is a method of treating a pulmonary disease comprising administering the in-vitro differentiated airway basal cells and compositions thereof. In another aspect, described herein is a disease model comprising patient-derived or genetically modified in-vitro differentiated airway basal cells and compositions thereof.